There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650
Recruiting
This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).
Gender:
All
Ages:
2 years and above
Trial Updated:
06/13/2024
Locations: Uni Of California Los Angeles, Los Angeles, California
Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Register for Updates
Cefixime Clinical Trial
NCT04958122
Recruiting
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Syphilis, Human Immunodeficiency Virus
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: LEO Pharma Investigational Site, Los Angeles, California
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341
Recruiting
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Ruane Clinical Research Group, Inc, Los Angeles, California
Conditions: HIV-1-infection
Register for Updates
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557
Recruiting
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
06/13/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Childhood Idiopathic Nephrotic Syndrome
Register for Updates
A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
NCT06218914
Recruiting
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Register for Updates
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632
Recruiting
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: University of California Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles, California
Conditions: Adult Acute Myeloid Leukemia
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/13/2024
Locations: Local Institution - 0212, Los Angeles, California +1 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: UCLA Clinical & Translational Research Center (CTRC), Los Angeles, California
Conditions: Systemic Lupus Erythematosus
Register for Updates
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
NCT03598244
Recruiting
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
Between 6 years and 21 years
Trial Updated:
06/12/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Primary Central Nervous System Neoplasm
Register for Updates
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395
Recruiting
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates